Antitumor efficacy of anti-GD2 IgG1 Is enhanced by Fc glyco-engineering Journal Article


Authors: Xu, H.; Guo, H.; Cheung, I. Y.; Cheung, N. K. V.
Article Title: Antitumor efficacy of anti-GD2 IgG1 Is enhanced by Fc glyco-engineering
Abstract: The affinity of therapeutic antibodies for Fcg receptors (FcgRs) strongly influences their antitumor potency. To generate antibodies with optimal binding and immunologic efficacy, we compared the affinities of different versions of an IgG1 Fc region that had an altered peptide backbone, altered glycans, or both. To produce IgG1 with glycans that lacked a1,6-fucose, we used CHO cells that were deficient in the enzyme UDP-Nacetylglucosamine: A-3-D-mannoside-b-1,2-N- Acetylglucosaminyltransferase I (GnT1), encoded by the MGAT1 gene. Mature N-linked glycans require this enzyme, and without it, CHO cells synthesize antibodies carrying only Man5-GlcNAc2, whichwere more effective in antibody-dependent cell-mediated cytotoxicity (ADCC). Our engineered IgG1, hu3F8-IgG1, is specific for GD2, a neuroendocrine tumor ganglioside. Its peptide mutant is IgG1-DEL (S239D/I332E/A330L), both produced in wildtype CHO cells. When produced in GnT1-deficient CHO cells, we refer to them as IgG1n and IgG1n-DEL, respectively. Affinities for human FcgRs were measured using Biacore T-100 (on CD16 and CD32 polymorphic alleles), their immunologic properties compared for ADCC and complement-mediated cytotoxicity (CMC) in vitro, and pharmacokinetics and antitumor effects were compared in vivo in humanized mice. IgG1n and IgG1n-DEL contained only mannose and acetylglucosamine and had preferential affinity for activating CD16s, over inhibitory CD32B, receptors. In vivo, the antitumor effects of IgG1, IgG1-DEL, and IgG1n-DEL were similar but modest, whereas IgG1n was significantly more effective (P < 0.05). Thus, IgG1n antibodies produced in GnT1-deficient CHO cells may have potential as improved anticancer therapeutics. © 2016 AACR.
Journal Title: Cancer Immunology Research
Volume: 4
Issue: 7
ISSN: 2326-6066
Publisher: American Association for Cancer Research  
Date Published: 2016-07-01
Start Page: 631
End Page: 638
Language: English
DOI: 10.1158/2326-6066.cir-15-0221
PROVIDER: scopus
PMCID: PMC4948116
PUBMED: 27197064
DOI/URL:
Notes: Article -- Export Date: 1 September 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nai-Kong Cheung
    650 Cheung
  2. Irene Y Cheung
    96 Cheung
  3. Hong Xu
    54 Xu
  4. Hong-Fen Guo
    74 Guo